Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment.
Background
Breast and gynaecological cancers (i.e. ovarian, endometrial, cervical, vaginal, vulval, and fallopian cancers) account for a significant amount of morbidity and mortality in women. In Europe an estimated 429,900 cases were diagnosed as breast cancer in 2006 (13.5% of all cancer cases) and 131,900 died from it, despite substantially improved treatment options (surgery, chemotherapy, radiation, hormonal and targeted therapies) [1] . Of female cancer survivors more than half had suffered from breast or gynaecological cancer [2] . 40% to 80% of these patients use complementary therapies additionally to well-established treatments [3] [4] [5] [6] [7] [8] . This includes a variety of medicinal plants, but also acupuncture, psychosocial support, yoga, art therapies and others. These are supportive measures to control symptoms, improve quality of life, boost the immune system, and possibly prolong life. Sufficient evaluation is often lacking, however, of the extent to which these therapeutic goals are achieved, as well as of issues relating to safety and mode of action. Medicinal plants in particular have a long history in the treatment of cancer and other conditions connected with tumours, and also play a major role in the development of new drugs today. Over 60% of currently used anti-cancer agents originally derive from natural sources such as plants, marine organisms and microorganisms [9] .
Across Europe, Viscum album L. extracts (VAE or European mistletoe, not to be confused with the Phoradendron species or "American mistletoe") are among the most common herbal extracts applied in cancer treatment [3, 7, 8, 10] . Viscum album is a hemi-parasitic shrub and contains a variety of biologically active compounds. Mistletoe lectins (ML I, II and III) have been most thoroughly investigated. MLs consist of two polypeptide chains: a carbohydrate-binding B-chain that can bind on cell surface receptors, which enables the protein to enter the cell [11] [12] [13] ; and the catalytic A-chain which can subsequently inhibit protein synthesis, due to its ribosome-inactivating properties, by removing an adenine residue from the 28S RNA of the 60S subunit of the ribosome [11] . Other pharmacologically relevant VAE compounds are viscotoxins and other low molecular proteins, VisalbCBA (Viscum album chitin-binding agglutinin) [14] , oligo-and polysaccharids [15, 16] , flavonoids [17] , vesicles [18] , triterpene acids [19] , and others [20, 21] . Whole VAE as well as several of the compounds are cytotoxic and the MLs in particular have strong apoptosis-inducing effects [22] [23] [24] . MLs also display cytotoxic effects on multidrug-resistant cancer cells (e.g. MDR+ colon cancer cells [25] ) and enhance cytotoxicity of anticancer drugs [26, 27] . In mononuclear cells VAE also possess DNA-stabilizing properties. VAE and its compounds stimulate the immune system (in vivo and in vitro activation of monocytes/macrophages, granulocytes, natural killer (NK) cells, T-cells, dendritic cells, induction of a variety of cytokines such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, GM-CSF, TNF-α, IFN-γ (overview see [20, 21] ). The cytotoxicity of human natural and lymphokine-activated killer cells, for instance, can be markedly enhanced in vitro by VAE rhamnogalacturonans, which bridge these killer cells with NK-sensitive or insensitive tumour cells [28, 29] . Furthermore, VAE seem to interfere with tumoural angiogenesis [30, 31] . Injected into tumour-bearing animals, VAE and several of their compounds (MLs, a 5 kDa protein not specified further, protein complexes isolated by Vester and colleagues, oligosaccharids) display growth-inhibiting and tumourreducing effects [20, 21] . Despite extensive experimental analyses of their biological properties, many questions regarding the precise mode of action of VAE still remain.
For clinical application VAE are made from mistletoes grown on different host trees [Host trees of VAE: Fir (Abies, A); maple (Acer, Ac); almond tree (Amygdalus, Am); birch (Betula, B); whitethorn (Crataegus, C); ash tree (Fraxinus, F); appletree (Malus, M); pine (Pinus, P); poplar (Populus, Po); oak (Quercus, Qu); willow (Salix, S); lime (Tilia, T), elm (Ulmus, U)], either by aqueous extraction, partly combined with fermentation, or by pressing procedures. Depending on host tree, harvesting time and extraction procedure, VAE vary in regard to their active compounds and biological properties. Different commercial VAE preparations are available, and a recombinant ML (rML) drug is currently being developed and tested in clinical trials [32, 33] .
Clinical effects of VAE in cancer have been investigated in a variety of studies and assessed in systematic reviews [34] [35] [36] [37] [38] [39] . These reviews, however, had inconsistent results, they are outdated, incomplete or concentrate on partial aspects. No review has yet assessed clinical and preclinical effects specifically and comprehensively for breast and gynaecological cancer, although there is widespread usage in these patients [3, 7] . Our primary aim was therefore to assess the potential therapeutic effectiveness of VAE, and their potential biological effects on breast and gynaecological cancer in clinical and preclinical studies.
For in vitro and animal experiments the criteria were adapted accordingly; unpublished material was not included however. In vitro experiments were restricted to cancer cells originating from human tumours.
Validity assessment and data abstraction
Criteria-based analysis was performed on the selected clinical studies to assess their methodological quality. Analyses were performed independently by two reviewers (GK, HK). There were no major differences in study assessment; disagreements were resolved by discussion. Criteria for assessing strength of evidence in controlled trials were adapted from the National Health Service Centre for Reviews and Dissemination [40] and from criteria for good methodology as already applied in earlier reviews on VAE trials [34, 36, 41] . Quality criteria were adjusted for cohort studies [36] . Data were abstracted by one reviewer (GK) and checked by a second reviewer (AG). When necessary, primary authors of the trials were contacted for additional information.
Regarding animal experiments we extracted data on study size, animal model, tumour type, tumour transfer, intervention, treatment schedule, outcome, physiological monitoring, side effects, dose-response, randomization, control treatment, blinding of outcome assessment, publication in a peer-reviewed journal, and funding source.
Results

Result of literature search
The literature search identified 306 references describing potential clinical studies (after deletion of duplicates). After deleting references only describing studies on immune modulation or toxicity or tolerability (phase I trial), or only on cancer sites other than breast or gynaecological, with retrospective evaluation, without quantification of results, or only investigating complex treatment regimes, or describing studies already published elsewhere, 48 potential studies were identified that met the inclusion criteria. Two trials [42, 43] , conducted in Poland, were excluded because of severe validity concerns: a collaborating scientist questioned the alleged randomization of treatment allocation, and no information could be obtained from the authors to clarify this question. One further RCT (on Lektinol ® and breast cancer by Schwiersch et al.) might have met the inclusion criteria but was unpublished and unavailable. Thus it was possible to include 46 studies in this review: 19 RCTs, 16 non-RCTs, and 11 single-arm cohort studies. Of the 46 studies, 43 were published (4 of these only as an abstract), 1 study was retrieved as a doctoral dissertation, and 2 were unpublished reports.
cancer hospitals. The studies were mainly conducted in Germany, but also in Austria, Switzerland, USA, Serbia, Russia, Bulgaria, Ukraine, Italy, Egypt, Israel, China, South Korea. Most studies were conducted in more than one centre. In 31 of the 32 studies published since 2000, the funding source was identifiable: three studies had public funding [44] [45] [46] , 17 a combination of public and industry funding, and 11 industry funding alone.
Controlled studies
The 19 RCTs [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] (Table 1) encompassed 2420 participants, 16 non-RCTs [49] [50] [51] [52] [53] 59, [64] [65] [66] [67] [68] [69] [70] [71] [72] (Table 2) encompassed over 6399 participants (the sample size of one control group was not published). Cancer sites studied were breast (n = 20), uterus (n = 4), ovary (n = 6), cervix (n = 4), and genital (n = 1). One RCT investigated malignant pleural infusion. 4 studies not only investigated gynaecological or breast cancer but other cancer types as well.
Stages ranged from early-detected to advanced disease. 33 studies had two arms, one trial had three, and one four arms. Endpoints were: survival (22 studies), tumour remission, recurrence or time to recurrence or metastases (8 studies), pleurodesis (1 study), QoL or coping with disease (11 studies), QoL or tolerability of concomitant chemotherapy, radiotherapy or surgery (13 studies). Length of follow-up varied from three days in one trial to -usually -months or years.
All treatment groups received conventional care when indicated, and most patients had undergone prior surgery. In 16 studies (9 RCTs and 7 non-RCTs) the combination of VAE treatment and concurrent chemotherapy, radio- I A) Protection against selection bias, especially by adequate randomization B) Minimization of heterogeneity by pre-stratification or matching C) Protection against observer bias by blinding of patient, care provider, and outcome assessor D) Protection against performance (treatment) bias by standardization of care protocol, documentation of all co-interventions, blinding of patients and care providers E) Protection against measurement (detection) bias by standardization of outcome assessment F) Protection against attrition (exclusion) bias, lost patients <10% or by intention-to-treat analysis (including non-adherers as randomized) plus perprotocol analysis (excluding non-adherers) in combination with sensitivity analysis, and by comparison of prognostic characteristics of lost patients and compliers G) Effect measurement relevant and well described H) Well-described intervention, patient characteristics, disease (diagnosis, stage, duration), previous therapy I) Well-described study design J) Well-described results K) Data quality assured by ICH-GCP guidelines, especially by monitoring + = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, -= not fulfilled II AR: attrition rate (dropouts, protocol deviations, withdrawals, patients did not receive treatment as allocated). III Assessment based only on an abstract IV Discrepancy in patient numbers in two presentations (30 and 33) , with corresponding discrepancy of results therapy or surgery was investigated. 13 of these studies assessed reduction of side effects from these cytoreductive therapies. Three trials directly compared VAE treatment versus chemotherapy treatment or versus radiation and hormones [60, 62, 66] . In most studies VAE therapy was used at least partly in an adjuvant setting after surgery or radiotherapy.
The commercial VAE applied were Iscador ® , Helixor ® , Eurixor ® or Lektinol ® . VAE dosage mostly followed general recommendations, starting with low doses and increasing to an individually still well-tolerated dosage, or treating according to lectin-content (in 6 trials) or leaving treatment modalities to the physician's discretion, which, it can likewise be assumed, followed general recommendations. VAE was injected subcutaneously except in three trials employing intravenous infusion or intrapleural instillation [48, 60, 65] . Treatment duration was often not specified and depended on primary endpoint and related follow-up, ranging from one single application (in one trial [65] ) to repeated applications over months and years. Control groups either received no further comparison treatment (n = 27), additional placebo application (n = 5), doxycycline (n = 1), Lentinan (n = 1) or radiation and hormones (n = 1). 4 trials had double-blinded treatment application.
Single-arm studies 11 prospective cohort studies [32, [44] [45] [46] [73] [74] [75] [76] [77] [78] [79] [80] (Table 6) included 1,130 patients. Cancer sites studied were breast (n = 6), ovary (n = 1), CIN (n = 1), malignant pleural effusion (n = 2) and malignant ascites (n = 2). 8 studies investigated several cancer types. Tumour stages were advanced or inoperable except in three studies. In most studies patients had received conventional treatment some time previously. Directly preceding or concurrent anti-cancer treatment had been applied in two studies (gemcitabine [44] , surgery [45] ). Nine studies assessed tumour remission; seven None (102) reported QoL or symptomatic relief. Two studies primarily investigated the toxicity profile, pharmakokinetics and potential interactions of either the combination of gemcitabine and VAE [44, 73] or of rML [32] , and secondarily assessed tumour behaviour. The commercial VAE remedies were Abnobaviscum ® /Viscum fraxini, Iscador, Helixor, Lektinol or Aviscumine ® (rML). VAE were applied subcutaneously (n = 6), intratumourally (n = 1), intrapleurally (n = 2), intraperitoneally (n = 2) or as an intravenous infusion (n = 1). Dosage depended on the preparation and mode of application; some treated according to lectin content, others started with a low dosage and increased successively, or started with high dosage and applied it consistently once weekly. For intrapleural and intraperitoneal (repeated) application, VAE was diluted in 5 to 15 ml or 100 ml solution. Treatment duration and follow-up ranged from weeks to, most commonly, months or years. Table 1 , 2 and 6 summarize the validity assessment. Methodological quality differed substantially in the reviewed studies. 19 trials had randomized treatment allocation. The RCTs were mostly small (median sample size n = 60, range 23-692), particularly when investigating survival (median n = 52). Although RCTs investigating QoL were only slightly larger (median n = 68), they nevertheless encompass 4 trials that largely met modern standards of clinical trials and three of them had a sample size above 200. In four of the RCTs the patients and physicians were blinded; three further RCTs had an active or a placebo control-treatment. -16 studies were non-randomized (median sample size n = 203, range 82-1442), 15 of them had controlled for confounding by close prospective (in one case retrospective) pair matching, by alternating treatment allocation and by multivariate analysis or propensity score (though in one study only for the main outcome parameter [69] ). -Assurance of data quality according to ICH-GCP ("Good Clinical Practice") or GEP ("Good Epidemiological Practice") guidelines was reported in 5 RCTs and 4 non-RCTs. Eight of the RCTs and 8 of the non-RCTs were embedded in the same large epidemiological cohort study. Most studies did not present a clear documentation of co-interventions. Regarding the other quality aspects, most studies -especially the more recent ones -were reasonably well designed and conducted.
Quality assessment
In the single-armed studies, study quality was reasonably good except in an unpublished report [80] and in an abstract publication [75] with too little information. Two studies had applied VAE in combination with or subsequent to conventional cancer treatment and one study had explored CIN, which has high spontaneous remission rates.
Characteristics of the preclinical studies
The in vitro cytotoxicity of different VAEs as well as isolated or recombinant lectins or their A-chain, viscotoxins, or other protein fractions were tested with different methods in a variety of human breast, ovarian, uterine, vulvar and cervical cancer cells [12, 20, 22, (Table 7) .
Retrolective pharmaco-epidemiological cohort study Trend improvement in symptom score, especially abdominal pain, abdominal pressure, and waking up at night due to shortness of breath IV N: Number of participants V Concomitant conventional oncological cytoreductive therapies in some of the patients VI L Well-described patient characteristic and disease (diagnosis, stage, duration), prognostic factors M Outcome parameter relevant and well described N Well-described intervention O Concomitant therapies well described P Outcome clearly described, temporal relationship between applied therapy and observed outcome precisely described Q Selection of patients excluded + = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, -= not fulfilled Animal studies 43 studies were found. 9 of these were excluded as they investigated: tumour-bearing eggs [111] , pre-incubation of tumour cells with VAE [112, 113] , different cancer types without differentiating the results accordingly [114] , or isolated VAE proteins that were unstable [115] . Of the remaining 34 experiments [96, 111, [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] (Tables 8  and 9 ), 28 had been conducted in mice and 6 in rats. 22 experiments had included 788 animals, (5-20 per treatment group), one included 282 VAE-treated animals (number of control animals were not reported), the other reports gave no details. 32 experiments investigated breast tumours (15 of these Ehrlich carcinoma, ECa), one uterus epithelioma and one ovarian cancer. 28 had used murine tumour models, 5 were of human origin and 1 an autochthonous model (methylnitrosurea-induced tumourigenesis). 24 experiments investigated whole VAE (two of these VAE-activated macrophages), two investigated isolated MLs, two rMLs, two investigated other isolated proteins, and four investigated polysaccharides ("Viscumsäure"). VAE were applied systemically in 17 experiments (subcutaneous, intraperitoneal, intratumoural on opposite site, intramuscular), local at the tumour site in 15 experiments (intraperitoneal, intratumoural, intramuscular), and without specification in two studies.
These experiments had been conducted in Germany, Switzerland, Austria, USA, India, Croatia and Serbia. 9 of the 34 experiments reported the funding source, 8 of these had public funding and one a combination of public and industry funding. 19 had been published since 1990 and 15 before . 21 were published in peerreviewed and 2 in other journals, 6 were published in scientific reference books, 1 as a conference abstract, and 4 in a patent specification. Published information was often insufficient and sometimes extremely sparse. 6 experiments reported randomized treatment allocation. Regarding the control group, placebo treatment was described in 13 experiments -five of these with identical application schedule to the verum treatment -, no treatment in 11 experiments, and 9 experiments gave no information. None of the experiments reported a blinded outcome assessment (but randomized treatment allocation and blinded outcome assessment are generally routine practice).
Outcome
We found substantial heterogeneity of the studies in terms of intervention, patient characteristics, clinical diagnosis, measured outcomes, design, methodological quality and potential positive and negative biases. We therefore regarded quantification of effect size by combining results as unreliable and decided on a non-quantitative synthesis and discussion. A subgroup of studies (2 RCTs, 2 nonRCTs on breast cancer), with a comparable design (all originating in the same epidemiological cohort study) had already been analysed in a quantitative meta-analysis [135] .
Results of controlled clinical studies are shown in Table 3 (survival), Table 4 (tumour behaviour) and Table 5 (QoL and tolerability of conventional cancer treatment); results of single-arm studies are shown in Table 6 .
Results of the preclinical studies are presented in Tables 7,  8 and 9 .
Breast cancer
Clinical studies Survival (Table 3 ) was investigated by 4 RCTs and 3 nonRCTs (one of these is shown with three subgroups in Table  3 ): Two RCTs reported a statistically significant benefit of VAE (of these one also included other tumour sites, and the other suffered from a major attrition rate without preventing bias by an intention-to-treat analysis), and two RCTs reported a small positive trend. The results of the latter two RCTs were also combined in an individual patient data meta-analysis; the result just missed significance (HR: 0.59, 95% CI: 0.34-1.02, p = 0.057) [135] . Two nonRCTs had observed a statistically significant benefit, and one a small positive trend. The results of two non-RCTs were additionally combined in an individual patient data meta-analysis, and showed highly significant results (HR: 0.43, 95% CI: 0.34-0.56, p < 0.0005) [135] . Tumour behaviour (Tables 4 and 6 ) was investigated by two RCTs, four non-RCTs and 4 single-arm studies. Four of the controlled studies combined VAE and conventional cancer treatment. These studies partly reported a benefit regarding disease recurrence and time to disease relapse and partly no difference; none found a disadvantage. Two single-arm studies reported tumour remission in 44-62% of patients after local application of high dosage VAE. Another study found no remission after the application of rML. QoL and the reduction of side effects of chemotherapy, radiation and surgery (Tables 5 and 6) were assessed by 11 RCTs, 6 non-RCTs and 4 single-arm studies: 19 of these 21 studies reported a benefit, mostly statistically significant, one study reported no QoL-benefit but a reduction of side effects, and the smallest of these studies found no difference. Three major pharmaco-epidemiological studies investigated patient charts and found reduced diseaseand therapy-associated symptoms in VAE-treated groups.
In preclinical studies (Tables 7, 8 , and 9) VAE and VAE compounds showed cytotoxic effects in cancer cells. VAE also counteracted growth factor-induced proliferation and migration in breast cancer cells [95] . In mice, VAE inhibited tumour growth in most cases, especially when applied locally and in high dosage. Survival was prolonged in most cases, and numbers of metastases and (page number not for citation purposes) [22] Iscador M, Qu, Abnobaviscum Fr
Inhibition of proliferation 0.1-1 mg/ml 0.01-1 mg/ml [81] KPL-1 Iscador Qu, M, A Iscador P ML I IC 50 0.1-0.3 mg/ml 1.94 mg/ml 141 ng/ml [22] Iscador M, Qu, Abnobaviscum Fr
Inhibition of proliferation 1 mg/ml 0,1-1 mg/ml [81] Iscucin ® A, M, P, C, Po, T, Qu, S Cytotoxicity 0.1 mg/ml [82] Iscador M ML I
No stimulation of cell proliferation 0.05-5 ng ML/ml 0.01-5 ng/ml [83] MCF-7 Iscador Qu, M, A Iscador P ML I IC 50 0.09-0.12 mg/ml 1.61 mg/ml 410 ng/ml [22] Lektinol IC 50 >10 ng ML I/ml [84] Iscador Qu, M, P (max. 1 or 1.5 mg/ml)
Inhibition of S-phase progression Induction of apoptosis [85] [86] [87] Iscador M Iscador P ML I Iscador Qu IC 50 No influence 185 μg/ml no activity 0.003 μg/ml 0.0015-15 μg/ml [88, 89] Viscotoxin isoforms (A1, A2, A3, B, 1-PS) Viscotoxin isoform U-PS GI 50 LC 50 0.02-0.8 μg/ml 0.6 to >1 μg/ml no activity [90] ML I A chain Inhibition of proliferation 0.5 μg/ml [91] ML I, ML II, ML III Inhibition of proliferation 1-10 ng/ml [91] TNF & ML I (100 ng/ml) Potentiation of TNF-cytotoxicity [92] Lektinol IC 50 0.003 μg/ml [93] Helixor P ML I IC 50 > 150 μg/ml 0.086 μg/ml [94] Iscucin M, P, C, Po, T, Qu, S Iscucin A, Pi Cytotoxicity 0.1 mg/ml no activity [82] MCF-7/ADR Lektinol IC 50 (SRB assay) 0.3 E-4 μg/ml [93] MAXF 401NL Helixor P ML I IC 50 0.66 μg/ml 0.003 μg/ml [94] Iscador M Iscador P ML I Iscador Qu IC 50 >70% growth inhibition < 3 μg/ml no activity 0.353 E-4 μg/ml 10 μg/ml [88, 89] MAXF 401 Lektinol IC 50 < 0.1 E-4 μg/ml [93] MAXF 1162 Lektinol IC 50 < 0.1 E-4 μg/ml [93] MAXF 449 Lektinol IC 50 0.2 E-4 μg/ml [93] MAXF MX1 Lektinol IC 50 < 0.1 E-4 μg/ml [93] MDA-MB-231 Lektinol IC 50 0.7 E-4 μg/ml [93] Helixor P ML I IC 50 135 μg/ml 0.041 μg/ml [94] MDA-MB-468 Helixor P ML 1 IC 50 47 μg/ml 0.006 μg/ml [94] MDA-MB-486-HER2 Iscador M Inhibition of epidermal growth factor-induced proliferation 0.5 μg/ml [95] Colo-824 Iscador M ML I
No stimulation of cell proliferation 0.05-5 ng ML/ml 0.01-5 ng/ml [83] HCC-1937 Iscador Qu, M, A Iscador P ML I IC 50 0.1 to 0.3 mg/ml 2.14 mg/ml 320 ng/ml [22] Iscucin A, M, P, C, Po, T, Qu, S Cytotoxicity 0.1 mg/ml [82] BT474 Helixor M, A Cytotoxicity (WST-1) Maximum (80 and 100%) with 25 mg/ml [96] Primary breast cancer Iscador M, Qu Abnobaviscum Fr
Mitochondrial activity (MTT) 50-80% with 0.1-0.001 mg/ml [81] Abnobaviscum M Inhibition of proliferation 0.5-50 μg/ml [97] ML I Inhibition of proliferation 1-50 ng/ml [20, 98] T47D ML I, II, III IC 50 > 0.1 -1 ng/ml [99] ML I A-chain Inhibition of proliferation 10 ng/ml [91] BT549 ML I A-chain Inhibition of proliferation 500 ng/ml [91] HBL100 ML I A-chain Inhibition of proliferation 100 ng/ml [91] Breast cancer cells ML II, ML III, viscotoxins Cytotoxicity [100] Ovarian cancer OVXF 1619L Helixor P ML I IC 50 119 μg/ml 0.100 E-3 μg/ml [94] OVXF 899L Helixor P ML I IC 50 >150 μg/ml 0.229 μg/ml [94] SKOV-3 (HER-2 expression) Recombinant ML I IC 50 Induction of apoptosis 0.033 ng/ml [101] OVCAR3 Iscador Qu, M (max. 1 or 1.5 mg/ml)
Inhibition of S-phase progression, Induction of apoptosis
No clear effect [87] OVXF 899 Lektinol IC 50 0.3 E-3 μg/ml [93] OVXF 1353 Lektinol IC 50 0.01 μg/ml [93] OVXF 1023 Lektinol IC 50 < 0.1 E-4 μg/ml [93] SKOV3 Lektinol IC 50 < 0.1 E-4 μg/ml [93] SK-UT-1B Lektinol IC 50 0.6-5.5 ng ML I/ml [84] ML I Inhibition of proliferation 0.5-500 ng/ml [98, 102] Iscador M ML I
No stimulation of cell proliferation 0.05-5 ng ML/ml 0.01-5 ng/ml [83] SK-UT-1 ML I Inhibition of proliferation 0.5-500 ng/ml [98, 102] MES-SA ML I Inhibition of proliferation 0.5-500 ng/ml [98, 102] Primary uterus cancer Abnobaviscum M Inhibition of proliferation 5-50 μg/ml [97] Vulvar cancer SK-MLS-1 Lektinol IC 50 2 to >5 ng ML I/ml [84] ML I Inhibition of proliferation: 0.5-500 ng/ml [98, 102] Iscador M ML I
No stimulation of cell proliferation 0.05-5 ng ML/ml 0.01-5 ng/ml [83] Cervical cancer HeLa TNF & ML I (100 ng/ml) Potentiation of TNF-cytotoxicity [92] ML I Inhibition of protein synthesis 100 μg/ml [12, 103] Protein fractions Complete inhibition of DNA-, RNA-synthesis Proliferation 1 μg/ml no effect [104] Viscotoxins IC 50 0.2-1.7 μg/ml [105] Helixor M Growth inhibition ≥ 0.01 mg/ml [106] Isorel ® Cytotoxicity 30 μg/μl [107] Isorel A, M, P, ML I Cytotoxicity > 1 μl/ml > 1 μg/ml [108] Iscador M Helixor M VAE M LC 50 16 μg/ml 35,4 μg/ml 3,9 μg/ml [109, 110] Iscador M, Qu Abnobaviscum Fr Growth inhibition 0.1-1 mg/ml 0.01 mg/ml [81] GI 50 : 50% growth inhibitory concentration LC 50 : 50% lethal concentration IC 50 : 50% inhibitory concentration MCF-7/ADR: adriamycin(doxorubicin)-resistant MCF-7 cell line HER: human epidermal growth factor receptor Iscador M c. Arg., sc, 0,2 ml/ day, 50 mg/week * 6 weeks 75% -16% [124] sc: subcutaneous; im: intramuscular; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week; qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span All experiments did have control groups, but these were only mentioned if necessary for results I Part of a screening programme for substances with anticancer activity (1,000 plant extracts from 107 plant species) II Relating to volume of ascites; effects greatest with therapy started on day -7 
Murine breast tumour in rats
Walker Carcinosarcoma Rats Polysaccharide ("Viscumsäure"), ip, qd * 6
Moderate effect [133] local recurrences were reduced after application of VAE or of VAE-activated macrophages; one study found no benefit. All experiments using local VAE application found a benefit in relation to survival and tumour-growth inhibition. In rats, no clear benefit of VAE could be seen. Results from applying isolated or recombinant VAE compounds were inconsistent: some moderate effects of proteins (e.g. lectins) or polysaccharides were observed in relation to survival and tumour growth, while others observed none or possibly also adverse outcomes.
Cervical cancer
Clinical studies: Survival (Table 3) was investigated by one RCT and three non-RCTs: all four reported a beneficial outcome which, however, was statistically significant only in the non-RCTs. Tumour behaviour (Table 4 ) was investigated by one non-RCT, which could not find an effect on disease recurrence or metastases mainly because these events scarcely occurred. One single-arm study reported 41% complete and 27% partial remissions in CIN after VAE application. QoL (Table 5) was assessed in one RCT and one non-RCT; both reported a statistically significant benefit.
Regarding preclinical studies (Table 7) , only HeLa cells were investigated; here VAE and protein fractions showed cytotoxic effects.
Uterus cancer
Clinical studies: Survival (Table 3) was investigated by two RCTs and two non-RCTs; three reported a statistically significant benefit while one found no difference. QoL (Table  5) was assessed by one RCT and one non-RCT; both found a statistically highly significant benefit.
Regarding preclinical studies (Tables 7 and 9 ), VAE and isolated ML I showed cytotoxic effects in different human uterus cancer cells. Concerning animal experiments, a patent specification mentions "moderate" effects of mistletoe polysaccharides on tumour growth in uterusepithelioma.
Ovarian cancer
Clinical studies: Two RCTs and two non-RCTs investigated the influence of VAE on survival (Table 3) and reported a benefit, one of each with statistical significance. Tumour behaviour (Table 4) was investigated by two RCTs, each combining VAE and chemotherapy (plus radiotherapy in one study): these reported comparable outcomes. The influence of VAE on QoL and tolerability of chemotherapy and radiation (Table 5 ) was investigated by three RCTs and one non-RCT; all of them reported a statistically significant positive effect. In one trial using an aggressive chemotherapy protocol, higher dosages of Cisplatin and Holoxan could be given in the VAE group as the side effects were less intense [63] . One single-arm study applied recombinant lectins in ovarian cancer but found no remission.
Regarding preclinical studies (Tables 7 and 9 ), VAE showed cytotoxic effects in various ovarian cancer cells. In SCID mice, rMLs led to increased survival and to more tumourfree animals at the highest and lowest dosage, while no effect was observed at the medium dosage.
Genital cancer
Clinical studies: One non-RCT (published in 1963) reported partly improved disease-specific survival (Table  3) . Regarding preclinical studies (Table 7) , VAE showed cytotoxic effects in vulvar cancer cells. Moderate effect [133] All experiments did have control groups, but these were only mentioned if necessary for results. sc: subcutaneous; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week; qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span. I Application of 10 μg/kg of proteins had toxic effects 
Other gynaecological tumour
Malignant effusion
Clinical studies: One RCT and four single-arm studies investigated treatment of malignant pleural effusion and ascites (originating from breast or ovarian cancer, among other cancer sites), and all reported substantial remission rates (Tables 4 and 6 ).
Safety
Tolerability was generally good. One case of urticaria and angioedema [56] and one case of "generalized reaction" [69] were described. Otherwise no major side effects or toxicity were reported. Frequent minor, dose-dependent and spontaneously subsiding symptoms included reactions at the injection site (swelling, induration, erythema, pruritus, local pain) and mild flu-like symptoms or fever.
In one study, local reactions intensified during concomitant chemotherapy [64] . A higher prevalence of depression was documented in the unadjusted data of a retrolective non-RCT [69] in VAE-treated patients; these patients also had a higher prevalence of other treatments such as hormones. After intrapleural instillation, VAE induced significantly fewer side effects than doxycycline [60] . No indication for an interaction of VAE and chemotherapy could be found (i.e. remission rate) and VAE had no influence on the plasma concentration of gemcitabine [44, 73] . No toxicity was observed in animal studies, except after application of high doses of an isolated protein complex with unknown constituents [132] .
Discussion
A variety of clinical studies and experiments have investigated the potential therapeutic effects of VAE and its compounds in breast and gynecological cancer, and predominantly reported positive effects. Nevertheless they have to be interpreted with caution and within their context.
The strongest and most consistent results from VAE in clinical studies concern QoL and improved tolerability of conventional treatment. QoL questionnaires included mostly well established and validated QoL instruments and one on psychosomatic self-regulation. The latter is a 16 item QoL instrument that measures competence and autonomy, in terms of the ability to actively adapt to stressful life situations and to restore well-being. [136] This tool has so far been exclusively used in studies focusing on complementary cancer treatments. Improvement was seen especially in relation to self-regulation, fatigue, sleep, nausea/vomiting, appetite, diarrhoea, energy, ability to work, enjoyment of life, depression, anxiety, pain, and general physical, emotional, and functional wellbeing (for more details see Kienle [55, 137] , due to its local reactions and mild flu-like symptoms. In the four blinded trials reviewed here, a considerable degree of unblinding was detected by asking patients and physicians in one study [55] ; and can be presumed in two other of these trials where substantially more VAE-treated patients reported local reactions than control patients [54, 57] . Other RCTs did not blind treatment application, as blinding is unreliable. Therefore questions will remain in "blinded" as well as in open trials even though in general cancer or non-cancer trials could not detect relevant improvements of QoL or disease symptoms due to suggestive administration of inert substances [138] [139] [140] . Nevertheless, the frequency, magnitude, duration and conditions of QoL or symptomatic improvement in the course of VAE treatment should be clarified in more detail. Especially relevant might be the further elucidation of possible effects on cancer-related fatigue (see also [141] ), which is one of the most disabling conditions in cancer patients, with only few therapeutic options for influencing it effectively [142] [143] [144] . Regarding simple prepost assessments of QoL in single-arm studies, it is probably unnecessary to state that they are generally not appropriate for judging influences on QoL, since it is affected by many factors.
Concerning survival (Table 3) , some of the RCTs show a statistically significant benefit while others show a statistical trend or no difference. Most of the non-RCTs (which included larger patient numbers) show a major impact. The validity of the studies is limited because of their small sample size (median only 52 participants per RCT), and because 8 of the 9 RCTs were imbedded in the same (large) epidemiological cohort study. This study was started in the 1970s, before modern standards of data quality control (ICH-GCP, GEP) were established, and it therefore does not fulfil modern standards in this respect. The 9 th RCT had enrolled more patients but was conducted even earlier, and suffers from a major attrition rate due to protocol violation [62]; the subsequent analysis followed the "as treated" instead of the "intention-totreat" principle [145] . Hence bias cannot be excluded. None of the survival studies was blinded, but survival is generally not easily affected by observer bias or suggestive effects [138] [139] [140] . Seen altogether, although results were consistent, questions regarding survival remain and validity of evidence is moderate at best. An independent, GCPconform trial with sufficient power would be desirable to further evaluate potential survival benefit.
Regarding tumour behaviour, evidence from RCTs is scanty; most benefits were shown in non-randomized studies. In single-arm studies of patients with no concomitant conventional cancer treatment, high-dose or local application of whole VAE led to substantial remission of tumour or malignant effusion. This was also observed in animal studies: local application resulted in tumour-growth inhibition and increased survival. However, this application and dosage is not standard and cannot be recommended widely due to potential risks of high dose or local application. With ordinary VAE application, schedule and dosage, spectacular tumour remissions tend to be the exception [20, 36] . No tumour remission was observed after application of rMLs. Remission in CIN cannot be distinguished from spontaneous remission rates, which are frequent in this indication.
Apart from the discussed issues, the following validity aspects have to be considered: An attrition rate above 10% was present in 10 RCTs. In 5 of these RCTs [49] [50] [51] 53] , patients were excluded before baseline assessment. Here the patients were provisionally enrolled into the matching and pairwise randomization procedure; subsequently they were asked for informed consent, and were excluded from the study if they declined, together with their matched twin. Even though the risk of bias with this procedure is small, as the complete randomization unit (patient pair) is excluded, the preferred conservative quality assessment in this review assessed these studies as not having excluded a drop-out bias. Of the remaining 5 trials, one had protocol violations in about 20% of patients as discussed above [62] , and one trial used an aggressive chemotherapy that inevitably had to be halted in several patients [63] . Three trials did not report details.
To reduce publication bias we also included unpublished studies and conducted a thorough literature search with extensive expert consultations. Regarding non-RCTs, bias by self-selecting the treatment is usually present in raw data. In particular, patients who choose complementary treatments differ substantially from patients not choosing them [70, 146] . It is therefore indispensable to conduct careful adjustment of baseline imbalances or matching [147] [148] [149] . This has been done to a varying degree in most studies except in one without any adjustment [64] , and in another which only adjusted for the main outcome parameter but not for the other reported results [69] . Without any adjustment, no conclusions can be drawn regarding the applied treatment. When conducted and analysed carefully, non-RCTs can provide valuable information regarding external validity and effectiveness, as they can investigate treatment effectiveness under routine conditions without distortion by the artificial and selective conditions of an RCT's experimental situation [150] .
In preclinical studies, VAE show substantial cytotoxic effects in cells originating from breast and gynaecological cancer, and display tumour-growth inhibition in animal studies. Cytotoxicity, especially of the MLs (which bind on human breast cancer cells [151] ), may be the cause of tumour reduction after local, intratumoural application of VAE. If systemically applied, the cytotoxicity of the MLs is of less relevance, as it is inhibited by serum glycoproteins [152] and by anti-ML antibodies [153] which are produced after a few weeks of VAE application. Therapeutic effects of the MLs were inconsistent and not very impressive in the reviewed experiments. However, in other tumour types, MLs have also shown substantial growth-inhibiting effects (e.g. [154] [155] [156] [157] ). Interestingly, in two experiments, the application of VAE-activated macrophages in mice not directly treated with VAE also showed tumour-growth inhibiting effects, while the application of non-activated macrophages had no effects [121] . Similarly in melanoma, the application of VAE-activated splenocytes inhibited metastasis [158, 159] .
In general, the predictive reliability of the preclinical studies for clinical application is fairly limited in most instances. Clinical cancer disease is insufficiently mimicked by animal models, with major differences regarding age, general condition, co-morbidity, invasiveness, metastases, antigenicity, immune system etc. The results of pre-clinical screening, especially for treatment of solid tumours, have therefore been largely disappointing. The models currently regarded as best for cytotoxic substances use patient-derived tumours that grow subcutaneously or orthotopically in nude mice, as in several cases reviewed here. Immuno-active substances may however still be insufficiently assessed in immune-deficient animals, as the main components of the immune system are missing (nude mice, for instance, cannot generate mature T-lymphocytes). Nevertheless, these preclinical experiments can provide important additional information for detecting the possible anti-cancer effects of medicinal plants, their active compounds, their mode of action and potential risks [20, [160] [161] [162] .
Safety aspects
Mistletoe therapy was well tolerated in the reviewed studies. Mild flu-like symptoms and local reactions at the injections sites are frequent, dose-dependent and self-limited. Allergic reactions can occur, and a few case reports of anaphylactic reactions exist [163] [164] [165] [166] . A phase I study, conducted at the NCCAM/NCI, investigated safety, toxicity and drug interactions between VAE and gemcitabine [73] and reported good tolerability, with neither doselimiting toxicity of the VAE nor any effects on the plasma concentration of gemcitabine [44] . Combination of VAE with chemotherapy or radiotherapy did not negatively influence remission rate in clinical and in animal studies [56, 63, 118] . A higher prevalence of depression in VAEtreated patients in one study was observed in raw data of a self-selected population, without adjustment of baseline imbalances. This difference can be ascribed to variations in the patient population; for instance, they differed markedly in the prevalence of hormone treatment. No toxicity was observed in animal experiments.
Conclusion
Preclinical and clinical studies investigating the influence of VAE and its isolated compounds on breast or gynaecological cancer suggest a benefit, with the strongest evidence in relation to QoL and tolerability of conventional anti-cancer treatments. Regarding survival, evidence is less conclusive; most of the clinical studies had a very small sample size (RCTs) and were embedded in the same large cohort study; therefore an independent trial would be needed. Tumour-growth inhibition has been insufficiently assessed in prospective clinical trials. Tumour regression seems not to have been connected with regular low-dose subcutaneous VAE treatment, but with high dose and local application. The latter has not yet been thoroughly assessed and is not generally recommended.
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